Recent regulatory filings indicate that Joanne M. Donovan, Chief Medical Officer at Edgewise Therapeutics, Inc. (NASDAQ:EWTX), has engaged in significant transactions involving the company's common stock. These activities include the sale of shares totaling roughly $2.09 million and the exercise of existing stock options.
The liquidation process was executed in two distinct stages. On May 4, 2026, Ms. Donovan sold 5,230 shares of common stock at an average price of $31.2931 per share. These transactions were spread across a pricing range between $30.72 and $31.66. The following day, May 5, 2026, she sold an additional 50,000 shares at an average price of $38.568 per share, with individual transaction prices ranging from $38.00 to $39.96.
These sales, which aggregate to a total value of $2,092,062, were conducted pursuant to a Rule 10b5-1 trading plan that the CMO adopted on December 26, 2025. At the time of these transactions, EWTX was trading at approximately $38.31, placing it near its 52-week high of $35 after a substantial 90% rise during the previous year.
In conjunction with the sales, Ms. Donovan also exercised options to acquire 50,000 shares of Edgewise Therapeutics common stock on May 5, 2026. The exercise price for these shares was $7.08 per share, resulting in a total acquisition value of $354,000. These options are subject to a vesting schedule of 1/48th of the shares each month starting from September 17, 2023, provided she remains with the company, and they are set to expire on August 17, 2033. Following these movements, Ms. Donovan's direct holdings consist of 4,367 shares of common stock and 75,000 stock options.
The insider activity follows a period of notable clinical developments for Edgewise Therapeutics. At the 2026 MDA Clinical and Scientific Conference, the company presented long-term data from its MESA open-label extension trial. The results indicated that participants with Becker muscular dystrophy treated with sevasemten maintained stable functional capacity over a 3.5-year period.
Wall Street analysts have responded to these developments and the company's pipeline with updated outlooks. Raymond James has reiterated a Strong Buy rating for EWTX with a price target of $46, while Truist Securities maintains a Buy rating and an identical price target. Furthermore, JPMorgan has increased its price target to $45, pointing toward anticipated catalysts within the pipeline, specifically regarding EDG-7500, an oral cardiac sarcomere modulator. Evercore ISI also raised its price target to $45 and maintained an Outperform rating, noting that the upcoming 12-week HCM data for EDG-7500, expected in the first half of 2026, is a significant factor.
Despite the optimistic analyst sentiment, some valuation metrics suggest caution. Analysis from InvestingPro indicates that the stock may currently be overvalued based on Fair Value metrics at its present trading levels.